Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) has been assigned an average rating of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $22.33.
Several brokerages have recently issued reports on IOVA. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of Iovance Biotherapeutics in a research note on Monday, August 12th. Piper Sandler downgraded Iovance Biotherapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the company from $19.00 to $10.00 in a research note on Monday, July 29th. StockNews.com upgraded Iovance Biotherapeutics to a “sell” rating in a research note on Monday, August 12th. Finally, UBS Group initiated coverage on Iovance Biotherapeutics in a research report on Thursday. They set a “buy” rating and a $17.00 price objective on the stock.
Get Our Latest Report on Iovance Biotherapeutics
Institutional Investors Weigh In On Iovance Biotherapeutics
Iovance Biotherapeutics Stock Up 1.0 %
Iovance Biotherapeutics stock opened at $10.67 on Friday. The stock’s 50 day moving average is $10.25 and its 200 day moving average is $9.89. The company has a market capitalization of $2.99 billion, a P/E ratio of -5.93 and a beta of 0.62. Iovance Biotherapeutics has a twelve month low of $3.47 and a twelve month high of $18.33.
Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.01. The firm had revenue of $31.11 million during the quarter, compared to the consensus estimate of $24.59 million. Iovance Biotherapeutics had a negative return on equity of 65.04% and a negative net margin of 1,343.27%. The company’s revenue was up 12969.7% on a year-over-year basis. During the same period last year, the company earned ($0.47) earnings per share. As a group, equities analysts expect that Iovance Biotherapeutics will post -1.26 EPS for the current year.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.
Recommended Stories
- Five stocks we like better than Iovance Biotherapeutics
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Texas Roadhouse Stock Steering for New Highs This Year
- 5 Top Rated Dividend Stocks to Consider
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.